慢性乙型肝炎合并脂肪肝临床与肝组织病理学分析*

doi:10.3969/j.issn.1672-5069.2017.01.026

Abstract

Yang Xiuzhen, Geng Aiwen, Xiao Li, et al.. Pathological and clinical features of patients with chronic hepatitis B and non-alcoholic fatty liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 101-102.

References

[1] 倪正平,黄飞,陆玲玲,等. 乙型肝炎随访对象近4年脂肪肝发生趋势及相关因素分析.中国保健营养,2012,22（10）:1610-1611.
[2] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组,非酒精性脂肪性肝病诊断标准。中华肝脏病杂志,2003,11（2）:71.
[3] 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案.中华肝脏病杂志,2000,8:324-329.
[4] Ott JJ,Stevens GA,Groeger J,et al.Global epidemiology of hepatitis B virus infection:new estimates of age-specific HBsAg seroprevalence and endemicity.Vaccine,2012,30:2212-2219.
[5] Lozano R,Naghavi M,Foreman K,et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012,380:2095-2128.
[6] Wang FS,Fan JG,Zhang Z,et al. The global burden of liver disease:the major impact of China. Hepatology, 2014,60:2099-2108.
[7] Nguyen LH,Chao D,Lim JK, et al. Histologic changes in liver tisssues from patients with chronic hepatitis B and minimal increases in lverls of alanine aminotransferase: a meta-analysis and systematic review.Clin Gastroenterol Hepatol, 2014,12:1262-1266.
[8] 贾莹,徐京杭,王军,等. HBeAg阴性慢性乙型肝炎和乙型肝炎肝硬化临床特点分析. 传染病信息,2011,24:176-178.
[9] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2015年版）. 实用肝脏病杂志,2016,19（3）：Ⅴ-ⅩⅩⅢ.
[10] Chook J B,Ngeow Y F,Yap S F,et al. Combined use of wild-type HBV precore and high serum iron marker as a potential tool for the prediction of cirrhosis in chronic hepatitis B infection. J Med Virol,2011,83（4）:594.
[11] Kawanaka M,Nishino K,Nakamura J,et al. Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving long-term nucleos（t）ide analogue therapy. Liver Cancer,2014, 3（1）:41-52.
[12] Sohn W,Paik YH,Kim JM,et al. HBV DNA and HBsAg levels as risk predictors of early and late recurrence ater curative resection of HBV-related hepatocellular carcinoma. Ann Surg Oncol,2014,21（7）:2429-2435.
[13] 艾敏,陈伟婵,沈薇. 2002例肝硬化患者的病因及并发症分析.临床肝胆病杂志,2013,29（5）:352-355.
[14] Wang CC,Tseng TC,Kao JH. Hepatitis B virus infection and metabolic syndrome:Fact or fiction. J Gastroenterol Hepatol,2015,30（1）:14-20.
[15] 陈仕祥,何维新,陈玺卿,等. 肝功能正常的慢性乙型肝炎病毒感染者肝组织病理分析. 人民军医,2011,54（4）:305-306.
[15] 杨霞.肝支付宝对慢性乙型肝炎患者抗病毒治疗效果的影响. 中国民抗医学,2015,26（24）:23-26.
[16] 陈阳琴,丁惠国. 脂肪性肝病对慢性乙型肝炎疾病进展及抗病毒应答的影响. 北京医学,2014,36（24）:1050-1052.
[17] Fung J,Swto WK,Lai CL,et al.Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B:implications for antiviral therapy. J Hepatol,2011,54（2）:195-200.
[18] Sksarin M,Kumarak L. Asian-pacific clinical practice guidelines on the management of hepatitis B:a 2015 update. Hepatol Int,2016,23（10）:1-99.

Pathological and clinical features of patients with chronic hepatitis B and non-alcoholic fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[3]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[4]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[5]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[6]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[7]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.
[8]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[9]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.
[10]	Wang Baodan, Li Meng, Gao Yu. Predictive factors of response to interferon-α antiviral therapy in children with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 345-348.
[11]	Fu Liang, Wu Dongbing, Ji Xinzun. Application of ARFI quantification in the evaluation of liver injuries in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 377-380.
[12]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[13]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[14]	Su Shuting, Zhong Yan, Mi Yuqiang.. Management of patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 293-296.
[15]	Zhang Feng, Yan Yan.. Implication of serum apolipoprotein B levels and its correlation with metabolic syndrome in checked-up individuals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 61-64.